New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
November 6, 2012
10:02 EDTTDC, SREV, SKM, ESRX, AT, KBW, ENR, ASEI, HME, BMRNOn The Fly: Analyst Downgrade Summary
Today's noteworthy downgrades include: American Science & Engineering (ASEI) downgraded to Hold from Buy at Benchmark Co.... Atlantic Power (AT) downgraded to Hold from Buy at Desjardins... BioMarin (BMRN) downgraded to Hold from Buy at Brean Capital... Energizer (ENR) downgraded to Market Perform from Outperform at Bernstein... Express Scripts (ESRX) downgraded to Hold from Buy at Jefferies... Home Properties (HME) downgraded to Underperform from Sector Perform at RBC Capital... KBW, Inc. (KBW) downgraded to Market Perform from Outperform at JMP Securities... SK Telecom (SKM) downgraded to Neutral from Outperform at Credit Suisse... ServiceSource (SREV) downgraded to Equal Weight from Overweight at Morgan Stanley... Teradata (TDC) downgraded to Sector Perform from Outperform at FBN Securities.
News For ASEI;AT;BMRN;ENR;ESRX;HME;KBW;SKM;SREV;TDC From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
September 4, 2015
16:22 EDTESRXExpress Scripts names Christopher McGinnis as Chief Accounting Officer
Effective September 2, Christopher McGinnis was appointed as the Vice President, Controller and Chief Accounting Officer of Express Scripts Holding Company and as the company's principal accounting officer as defined by the SEC. Christopher Knibb, who previously served as the principal accounting officer, continues employment at Express Scripts as Vice President, Financial Planning and Analysis.
September 2, 2015
11:12 EDTSREVServiceSource management to meet with JMP Securities
Subscribe for More Information
September 1, 2015
10:05 EDTBMRNOn The Fly: Analyst Initiation Summary
Today's noteworthy initiations include: 8point3 Energy (CAFD) initiated with an Equal Weight at Barclays... AMAG Pharmaceuticals (AMAG) initiated with an Outperform at Raymond James... Acadia (ACHC) initiated with an Outperform at Leerink... Acorda Therapeutics (ACOR) initiated with a Market Perform at Raymond James... Alexion (ALXN) initiated with a Strong Buy at Raymond James... Amedisys (AMED) initiated with an Outperform at Wells Fargo... Amgen (AMGN) initiated with a Market Perform at Raymond James... Amplify Snack Brands (BETR) initiated with a Neutral at Credit Suisse... BioMarin (BMRN) initiated with an Outperform at Raymond James... Biogen (BIIB) initiated with a Strong Buy at Raymond James... Celgene (CELG) initiated with a Strong Buy at Raymond James... CoreLogic (CLGX) initiated with a Neutral at SunTrust... Digi International (DGII) initiated with an Overweight at Stephens... First Solar (FSLR) initiated with an Overweight at Barclays... LHC Group (LHCG) initiated with an Outperform at Wells Fargo... Lancaster Colony (LANC) initiated with a Buy at BB&T... McCormick (MKC) initiated with a Buy at BB&T... NephroGenex (NRX) initiated with a Buy at H.C. Wainwright... Omega Protein (OME) initiated with a Hold at BB&T... Preferred Apartment (APTS) initiated with an Outperform at FBR Capital... Qorvo (QRVO) initiated with an Outperform at CLSA... Regeneron (REGN) initiated with an Outperform at Raymond James... Skyworks (SWKS) initiated with an Outperform at CLSA... SunPower (SPWR) initiated with an Equal Weight at Barclays... TESARO (TSRO) initiated with a Strong Buy at Raymond James... Ultragenyx (RARE) initiated with an Outperform at Raymond James... VEREIT (VER) initiated with a Buy at Goldman... Westmoreland (WLB) initiated with an Outperform at BMO Capital.
August 31, 2015
19:25 EDTBMRNBioMarin initiated with an Outperform at Raymond James
Subscribe for More Information
08:36 EDTBMRNBioMarin announces two oral presentation at Study of Inborn Errors of Metabolism
BioMarin Pharmaceutical announced that the company will present data in two oral and 19 poster presentations at the Society for the Study of Inborn Errors of Metabolism 2015 Annual Meeting which will be held on September 1-4 in Lyon, France. In an oral platform session, long-term efficacy and safety data from a Phase 2 extension study of pegvaliase, or PEG-PAL, rAvPAL-PEG, BMN 165, in adults with phenylketonuria, or PKU, will be presented. PKU is a rare genetic condition in which the body cannot metabolize the essential amino acid phenylalanine. Designated Orphan Drug status in the United States and European Union, pegvaliase is an enzyme substitution therapy that is designed to substitute phenylalanine ammonia lyase for phenylalanine hydroxylase, the enzyme deficient in people with PKU. A separate oral platform presentation will provide an overview of the reveglucosidase alfa, or BMN 701, clinical program in late onset Pompe disease. In addition, the overview will summarize the three ongoing trials; the ongoing Phase 3 INSPIRE trial, a switchover study designed to assess safety and efficacy of reveglucosidase alfa in patients previously treated with enzyme replacement therapy; an observational study in patients with late onset Pompe disease; and a transdiaphragmatic stimulation study in late onset Pompe patients treated with reveglucosidase alfa. The overview also includes a review of nonclinical activity as well as interim safety and efficacy results in treatment naive, late-onset Pompe patients treated with reveglucosidase alfa. Pompe disease is an inherited condition caused by the deficiency in the enzyme acid alpha-glucosidase, which leads to progressive weakening of muscles in the body, including diaphragm muscles essential for breathing. Reveglucosidase alfa is a novel fusion protein of insulin-like growth factor 2 and acid alpha-glucosidase, designed to target delivery to cell structures called lysosomes where the enzyme is most needed.
August 28, 2015
10:02 EDTTDCOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
07:24 EDTTDCTeradata downgraded to Neutral from Overweight at Atlantic Equities
Subscribe for More Information
August 27, 2015
19:14 EDTESRXExpress Scripts to cover both Repatha, Praluent for now, Bloomberg says
Subscribe for More Information
12:57 EDTBMRNFDA will approve Sarepta and BioMarin DMD drugs, Feuerstein says
TheStreet's biotech reporter Adam Feuerstein predicts that the FDA will approve both Biomarin's (BMRN) drisapersen and Sarepta's (SRPT) eteplirsen, which are both drugs to treat Duchenne muscular dystrophy, adding that the agency has been "essentially approving every drug that comes before it" and that it "can't and won't" say no to two drugs meant to improve the lives of kids with a fatal disease. Feuerstein noted he doesn't think the drugs are equivalent and he's still in the "eteplirsen is better than drisapersen" camp. Reference Link
08:35 EDTBMRNMedivation price target raised to $166 at William Blair after talazoparib deal
Subscribe for More Information
August 26, 2015
13:38 EDTBMRNSarepta rises after FDA accepts muscular dystrophy drug application
Subscribe for More Information
09:02 EDTSKMCiena says 5430 Packet Optical Platform being deployed by SK Telecom
Subscribe for More Information
August 24, 2015
13:54 EDTBMRNFly Watch: Sarepta upgraded ahead of FDA deadline on DMD drug
The 60-day FDA review period for Sarepta's (SRPT) rolling NDA submission for its Duchenne muscular dystrophy drug eteplirsen ends tomorrow, Tuesday, August 25. Piper Jaffray is among research firms taking a bullish stance on the stock ahead of tomorrow's deadline. BACKGROUND: Eteplirsen is an "exon skipping" treatment that attempts to bypass genetic mutations to allow improved functioning of the affected gene. On August 21, Sarepta announced that the FDA granted a rare pediatric disease designation for eteplirsen, in addition to its previous orphan designation and fast track status. Piper Jaffray's Edward Tenthoff noted today that the drug could see a February 2016 PDUFA date, potentially yielding "blockbuster sales" for the company. Importantly, BioMarin's (BMRN) drisapersen is slightly ahead of eteplirsen's approval process with a December 27 PDUFA date, posing a potential competitive risk for Sarepta. PDUFA dates are FDA deadlines for approving new drugs, normally coming within 6 or 10 months of an NDA acceptance depending on the drug's priority status. ANALYST TAKE: Tenthoff stated in note to investors this morning that he expects the Food and Drug Administration to accept the New Drug Application for Sarepta's eteplirsen at the end of its 60-day review period tomorrow. Additionally, Tenthoff sees a joint advisory committee for eteplirsen and the similar drisapersen from BioMarin on November 23-24. On May 19, Sarepta said it held pre-NDA meetings with the FDA, and Piper Jaffray said it believes the company has now met all of the agency's information requests. The analyst upgraded Sarepta to Overweight from Neutral and hiked his price target to $48 from $28 and now values eteplirsen at $1.3B, up from $919M previously. PRICE ACTION: Shares of Sarepta Therapeutics are up roughly 1% in intraday trading to $34.21. The stock jumped about 60% on May 20 after the company announced its mid-year NDA plans for eteplirsen. BioMarin shares, meanwhile, are down 2% to $123.59 this afternoon.
07:02 EDTBMRNMedivation to acquire worldwide rights to Talazoparib from BioMarin
Medivation (MDVN) and BioMarin Pharmaceutical (BMRN) have entered into an asset purchase agreement under which Medivation will acquire all worldwide rights to talazoparib, a highly-potent, orally-available poly ADP ribose polymerase inhibitor currently in a Phase 3 study for the treatment of patients with deleterious germline BRCA 1 or BRCA 2 mutations and locally advanced and/or metastatic breast cancer. Under the agreement, Medivation will be responsible for all research, development, regulatory and commercialization activities for all indications on a global basis. Under the terms of the agreement, Medivation will pay BioMarin $410 million upfront, up to an additional $160 million upon the achievement of regulatory and sales-based milestones and mid-single digit royalties for talazoparib. At the closing of the transaction, Medivation will assume all financial obligations associated with the development and commercialization of talazoparib. The closing of the transaction is conditioned on the expiration or termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act. The transaction is anticipated to close in 2015.
August 23, 2015
14:15 EDTTDCTeradata shares remain unattractive, Barron's says
Teradata shares saw a positive blip after a recently-announced $500M repurchase program, but the stock is still "best viewed from the sidelines," Barron's contends in its 'Follow Up' column, citing the likelihood of multiple contractions and earnings revisions. Reference Link
August 21, 2015
09:38 EDTBMRNUBS global healthcare analysts hold an analyst/industry conference call
Subscribe for More Information
06:23 EDTBMRNUBS sees 'meaningful' upside to BioMarin on positive Hemophilia data
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use